Rivaroxaban versus dalteparin for the treatment of cancer-associated venous thromboembolism: a systematic review and meta-analysis.

Ann Med Surg (Lond) · 2025 · PMC11981406 · PMID 40213232

Europe PMC DOI

hedged sentences

0.0400

closest p · 0.8× alpha

0.0500

boldest claim

The sentences

borderline significantP = 0.04actually significant

The CIs barely exclude 1, indicating a borderline significant result ( P = 0.04).

also in 2,946 other papers

marginally nonsignificantP = 0.05actually significant

Rivaroxaban was associated with a significant reduction in deep vein thrombosis (DVT) recurrence (OR: 0.75, P = 0.04) and a marginally nonsignificant reduction in pulmonary embolism recurrence (OR: 0.73, P = 0.05).

also in 126 other papers

did not reach statistical significanceno p-value reported

Nonsignificant bleeding events were slightly higher with rivaroxaban but did not reach statistical significance.

also in 39,124 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.